Soluble CD105 is prognostic of disease recurrence in prostate cancer patients

in Endocrine-Related Cancer

Correspondence should be addressed to N A Bhowmick: bhowmickn@cshs.org
Restricted access

While the overall 5-year survival rate for prostate cancer is near 100%, up to 35% of patients will develop recurrent disease. At the time of prostatectomy, prostate-specific antigen (PSA) is used to guide primary therapy with the goal of curative intervention. It can be valuable to know when primary therapy may not in fact be curative, so that subsequent adjuvant therapy can be administered at an early stage to limit progression. We examined prostate cancer patients with PSA ≤10 ng/mL that were all subjected to prostatectomy with at least 5 years of follow-up (n = 181). Based on data that endoglin (CD105) signaling in the tumor can contribute to prostate cancer progression, we examined the expression of soluble CD105 (sCD105) in the patient plasma. To determine the relation of plasma sCD105 measures to cellular CD105 in tissues, we tested an independent set of prostate cancer tissues and paired plasma (n = 31). Elevated sCD105 was found to be associated with recurrence-free survival of prostate cancer patients. Further, sCD105 levels in patient plasma were inversely correlated with cellular CD105 expression. This translational study supported preclinical data demonstrating the pro-tumorigenic capacity of cellular CD105 and provide a blood-based biomarker, sCD105, for prostate cancer recurrence in prostatectomy patients with PSA levels ≤10 ng/mL.

 

      Society for Endocrinology

All Time Past Year Past 30 Days
Abstract Views 103 103 103
Full Text Views 10 10 10
PDF Downloads 4 4 4
  • AllmerCSargentDJ 2000 . In SAS User's Group International Proceedings (SUGI28), paper 201–28. (available at: https://support.sas.com/resources/papers/proceedings/proceedings/sugi28/201-28.pdf)

    • Search Google Scholar
    • Export Citation
  • BollaMvan PoppelHColletteLvan CanghPVekemansKDa PozzoLde ReijkeTMVerbaeysABossetJFvan VelthovenR, 2005 Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 572–578. (https://doi.org/10.1016/S0140-6736(05)67101-2)

    • Search Google Scholar
    • Export Citation
  • BollaMvan PoppelHTombalBVekemansKDa PozzoLde ReijkeTMVerbaeysABossetJFvan VelthovenRColombelM, 2012 Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2018–2027. (https://doi.org/10.1016/S0140-6736(12)61253-7)

    • Search Google Scholar
    • Export Citation
  • CoxD 1986 Citation-classic – regression-models and life-tables. Current Contents/Agriculture Biology and Environmental Sciences 42 16.

    • Search Google Scholar
    • Export Citation
  • DalesJPGarciaSBonnierPDuffaudFAndrac-MeyerLRamuzOLavautMNAllasiaCCharpinC 2003 CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. American Journal of Clinical Pathology 374–380. (https://doi.org/10.1309/1kf54l6rb625556w)

    • Search Google Scholar
    • Export Citation
  • ErdemOTaskiranCOnanMAErdemMGunerHAtaogluO 2006 CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecologic Oncology 1007–1011. (https://doi.org/10.1016/j.ygyno.2006.06.010)

    • Search Google Scholar
    • Export Citation
  • FaisalFATosoianJJHanMMacuraKJPavlovichCPLotanTL 2019 MP09-05 clinical, pathologic, and oncologic findings of radical prostatectomy patients with extraprostatic extension diagnosed on pre-operative prostate biopsy. Journal of Urology 201 e108–e109. (https://doi.org/10.1097/01.JU.0000555129.46273.1b)

    • Search Google Scholar
    • Export Citation
  • FonsattiEAltomonteMNicotraMRNataliPGMaioM 2003 Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 6557–6563. (https://doi.org/10.1038/sj.onc.1206813)

    • Search Google Scholar
    • Export Citation
  • FreedlandSJHumphreysEBMangoldLAEisenbergerMDoreyFJWalshPCPartinAW 2005 Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 433–439. (https://doi.org/10.1001/jama.294.4.433)

    • Search Google Scholar
    • Export Citation
  • FujitaKEwingCMChanDYMangoldLAPartinAWIsaacsWBPavlovichCP 2009 Endoglin (CD105) as a urinary and serum marker of prostate cancer. International Journal of Cancer 664–669. (https://doi.org/10.1002/ijc.24007)

    • Search Google Scholar
    • Export Citation
  • GandagliaGBrigantiAClarkeNKarnesRJGraefenMOstPZietmanALRoachM3rd 2017 Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. European Urology 689–709. (https://doi.org/10.1016/j.eururo.2017.01.039)

    • Search Google Scholar
    • Export Citation
  • GrambschPMTherneauTM 1994 Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 515–526. (https://doi.org/10.1093/biomet/81.3.515)

    • Search Google Scholar
    • Export Citation
  • KapurNKMorineKJLetarteM 2013 Endoglin: a critical mediator of cardiovascular health. Vascular Health and Risk Management 195–206. (https://doi.org/10.2147/VHRM.S29144)

    • Search Google Scholar
    • Export Citation
  • KatoMPlacencio-HickokVRMadhavAHaldarSTripathiMBilletSMishraRSmithBRohena-RiveraKAgarwalP, 2019 Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene 716–730. (https://doi.org/10.1038/s41388-018-0461-3)

    • Search Google Scholar
    • Export Citation
  • KumarSGhellalALiCByrneGHaboubiNWangJMBundredN 1999 Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Research 856–861.

    • Search Google Scholar
    • Export Citation
  • LiCGuoBWilsonPBStewartAByrneGBundredNKumarS 2000 Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. International Journal of Cancer 122–126. (https://doi.org/10.1002/(sici)1097-0215(20000320)89:2<122::aid-ijc4>3.0.co;2-m)

    • Search Google Scholar
    • Export Citation
  • LiuYJovanovicBPinsMLeeCBerganRC 2002 Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 8272–8281. (https://doi.org/10.1038/sj.onc.1206117)

    • Search Google Scholar
    • Export Citation
  • MadhavAAndresADuongFMishraRHaldarSLiuZAngaraBGottliebRZumstegZSBhowmickNA 2018 Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 4385–4397. (https://doi.org/10.1038/s41388-018-0278-0)

    • Search Google Scholar
    • Export Citation
  • NikueiPRajaeiMMalekzadehKNejatizadehAMohseniFAtashAbParvarA 2017 Accuracy of soluble endoglin for diagnosis of preeclampsia and its severity. Iranian Biomedical Journal 312–330. (https://doi.org/10.18869/acadpub.ibj.21.5.312)

    • Search Google Scholar
    • Export Citation
  • PaauweMSchoonderwoerdMJAHeldermanRFCPHarryvanTJGroenewoudAvan PeltGWBorRHemmerDMVersteegHHSnaar-JagalskaBE, 2018 Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis. Clinical Cancer Research 6331–6344. (https://doi.org/10.1158/1078-0432.CCR-18-0329)

    • Search Google Scholar
    • Export Citation
  • PrensnerJRRubinMAWeiJTChinnaiyanAM 2012 Beyond PSA: the next generation of prostate cancer biomarkers. Science Translational Medicine 127rv3. (https://doi.org/10.1126/scitranslmed.3003180)

    • Search Google Scholar
    • Export Citation
  • SaadRSEl-GoharyYMemariELiuYLSilvermanJF 2005 Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Human Pathology 955–961. (https://doi.org/10.1016/j.humpath.2005.06.019)

    • Search Google Scholar
    • Export Citation
  • SchemperMSmithTL 1996 A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 343–346. (https://doi.org/10.1016/0197-2456(96)00075-x)

    • Search Google Scholar
    • Export Citation
  • SchmidtC 2017 Reconsidering prostate cancer screening. Journal of the National Cancer Institute 1–2. (https://doi.org/10.1093/jnci/djw337)

    • Search Google Scholar
    • Export Citation
  • SharmaNSeftorRESeftorEAGrumanLMHeidgerPMJrCohenMBLubaroffDMHendrixMJ 2002 Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 189–201. (https://doi.org/10.1002/pros.10048)

    • Search Google Scholar
    • Export Citation
  • SiegelRLMillerKDJemalA 2017 Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 7–30. (https://doi.org/10.3322/caac.21387)

  • SvatekRSKaramJARoehrbornCGKarakiewiczPISlawinKMShariatSF 2008 Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clinical Cancer Research 3362–3366. (https://doi.org/10.1158/1078-0432.CCR-07-4707)

    • Search Google Scholar
    • Export Citation
  • TakahashiNKawanishi-TabataRHabaATabataMHarutaYTsaiHSeonBK 2001 Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clinical Cancer Research 524–532.

    • Search Google Scholar
    • Export Citation
  • TanakaFOtakeYYanagiharaKKawanoYMiyaharaRLiMYamadaTHanaokaNInuiKWadaH 2001 Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clinical Cancer Research 3410–3415.

    • Search Google Scholar
    • Export Citation
  • TaskiranCErdemOOnanAArisoyOAcarAVuralCErdemMAtaogluOGunerH 2006 The prognostic value of endoglin (CD105) expression in ovarian carcinoma. International Journal of Gynecological Cancer 1789–1793. (https://doi.org/10.1111/j.1525-1438.2006.00658.x)

    • Search Google Scholar
    • Export Citation
  • TeradaNAkamatsuSKobayashiTInoueTOgawaOAntonarakisES 2017 Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology 565–573. (https://doi.org/10.1177/1758834017719215)

    • Search Google Scholar
    • Export Citation
  • WikstromPLissbrantIFStattinPEgevadLBerghA 2002 Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 268–275. (https://doi.org/10.1002/pros.10083)

    • Search Google Scholar
    • Export Citation
  • YouSKnudsenBSErhoNAlshalalfaMTakharMAl-Deen AshabHDavicioniEKarnesRJKleinEADenRB, 2016 Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Research 4948–4958. (https://doi.org/10.1158/0008-5472.CAN-16-0902)

    • Search Google Scholar
    • Export Citation
  • ZhaoSGChangSLErhoNYuMLehrerJAlshalalfaMSpeersCCooperbergMRKimWRyanCJ, 2017 Associations of luminal and basal subtyping of prostate cancer With prognosis and response to androgen deprivation therapy. JAMA Oncology 1663–1672. (https://doi.org/10.1001/jamaoncol.2017.0751)

    • Search Google Scholar
    • Export Citation